Showing posts with label 2013. Show all posts
Showing posts with label 2013. Show all posts

Tuesday, October 1, 2013

Congress Speaks Up for Community Pharmacies’ Compounding Services Published October 1, 2013


By Kevin Schweers
Three days before today’s government shutdown produced by partisan gridlock, Republicans and Democrats came together to approve drug safety legislation and re-affirm their support for compounding services provided by independent community pharmacies.
On a voice vote, the House of Representatives approved H.R. 3204, The Drug Quality and Security Act, legislation endorsed by NCPA, that responds to the tragic 2012 meningitis outbreak and adopts supply chain protections. The legislation is currently awaiting approval by the Senate. In the debate preceding the vote, lawmakers discussed how the bill protects community pharmacies’ ability to continue to compound drugs for their patients and asserted their intent to monitor its implementation to ensure it does not inadvertently infringe upon long-accepted compounding pharmacy practices.
“Mr. Speaker, this bill upholds the current section 503(a) of the law, and provides it with the clarity that FDA needs by eliminating the unconstitutional provisions,” said House Energy and Commerce Committee Chair Fred Upton (R-Mich.). “The bill also requires FDA to engage in meaningful communication with State boards of pharmacy. Further, under this bill, entities engaged in sterile drug compounding can voluntarily register with FDA and operate under FDA regulation. Finally and importantly, this bill protects traditional pharmacy compounding that occurs in community pharmacies across the country. That’s why the bill has the support of the National Community Pharmacists Association, and I would like to thank them for working with us so closely.”
Health Subcommittee Chair Joe Pitts (R-Penn.) opened his remarks noting that, “First, the bill would protect traditional pharmacies and clarify laws related to human drug compounding in response to last year’s nationwide meningitis outbreak – one of the largest public health crises in recent memory.” He also cited NCPA as one of the bill’s supporters, among other industry groups.
From the Democratic side of the aisle, Health Subcommittee Ranking MemberFrank Pallone (D-N.J.) added that, “The bill will permit compounders who wish to practice outside the scope of traditional pharmacy to register as outsourcing facilities, but those who choose to remain traditional pharmacies will continue to be regulated as they are under current law.”
continue to read

HRT Risks May Vary by Type of Estrogen Drug Published: Sep 30, 2013 | Updated: Oct 1, 2013

read here

Question of the Day October 1, 2013, Is anyone including Congress, the FDA, and State Boards of Pharmacy, paying attention to what is going on in the compounding pain medication world? The discussion on CafePharma board is very telling.


ny pain reps looking to make 10K to 40K per month on the side?

With all the connections you Pfizer reps have and are paid so little in comparison to the huge revenue I was just wondering if any of you would be interested in earning an extra 10K to 40K per month? Our company not only has a compounding pharmacy that you can promote but also 2 additional services that our reps promote with one being the industry leader in Genetic DNA testing via oral swab. The need for personalized medicine is growing rapidly and physicians are looking for genetic help to pick which medication is right or wrong for a patient and what dose they should start them on. The third service is a drug testing confirmation lab.
The real money maker for most reps in the compounding pharmacy which is why the industry is exploding right now. Everyone has seen Voltaren Gel promoted in your offices and it only has one active ingredient which is Diclofenac with a 1% concentration. Our pharmacy combines an NSIAD like Diclofenac but with at least a 3% concentration along with many other active ingredients to offer a product that typically offers much better pain reduction and is applicable to many more conditions and patients. Doesn't it make perfect sense that if you take that NSAID along with a muscle relaxer, a neuropathic pain med like Gabapentin, and throw in a topical anesthetic that you could treat a wide range of pain patients? Considering that we have meds to treat wounds and scar and that the aver reimbursement is around $1,800 per script and a rep earning 20% to 24% commission you can see why we had a rep work 4 hours in their first week working just Thursday & Friday and earned $2,500 off of 3 physicians. When they went back on Monday the physician had already written 7 new scripts so they could easily end up earning about 11K this week. If you consider that we pay a commission on every scripts whether it is a new RX or a refill you can see why reps are earning 10K to 40K per month. If you can find 20 physicians to write just 1 script per week you should earn about 28K per month. Keep in mind that those do not have to be new scripts, that could be 10 physicians who wrote 1 script per week last month and those patients got refills and you are right back at 20 scripts per week. When you factor how many scripts you might get in the third month you see why this is so attractive. You are a 1099 rep which means you are your own boss with no reports to turn in, no one micromanaging you, you can be at the beach every day and never make another sales call but if your physicians keep sending in scripts we keep paying you month after month year after year. Let's just say that there are a lot of reps both pharmaceutical and medical device that are finally jumping up in the morning excited about going to work as they finally are getting to work for themselves. Big pharma always talks about taking ownership and running the territory like you own it but they never pay you like you own it. You never have any quotas or sales number to hit and it’s the best residual income you will ever earn. The biggest hurdle reps have it getting past their concern that this is real and not some scam but it doesn't take much research to find out this industry is exploding. If you are interested you can go to our website at www dot SupremeMedSolutions dot com or you can email me at tisley at chartertn dot net. We offer the highest commission in the industry and multiple products you can sell and earn that high residual income on. What have you got to lose in finding out a little more info?

Quoted from CafePharma Board found here

Sunday, September 22, 2013

Eight Question of the Day, September 22, 2013, Will the slow progress of Congress in passing legislation to deal with the compounding pharmacy problem have any impacts on whether some in the House and Senate get reelected? Would the passage of federal compounding legislation help them in getting reelected?


Seventh Question of the Day, September 22, 2013, In the interest of transparency why doesn't the FDA make all 483 inspection reports available on its website?


Sixth Question of the Day, September 22, 2013, Which version the House or Senate version of the compounding legislation would be more likely to protect the health and safety of the public?


Fifth Question of the Day September 22, 2013 Which version of the compounding legislation the house or the senate version will help more people be employed? Which version will cause more small, local business owners to close up shop?


Fourth Question of the Day, September 22, 2013 Since there appears to be wide spread corruption and lack of ability to police ones on self among the State Board of Pharmacies when it comes to Compounding Pharmacies and Pharmacists Should Congress Consider Tasking the Department of Justice With a Priority of Criminal Investigations into this Area and Provide It With Dedicated Positions to Handle Pharmacy and Prescription Law Crimes in additon to the already mandated Health Care Fraud Positions.


Third Question of the Day, September 22, 2013 In light of the fact very few state boards of pharmacy have started to strictly and swiftly enforce state compounding laws, regulations and rules against compounding pharmacies and pharmacists, why hasn't Congress taken prompt action to give the FDA much needed clearly defined authority over compounding pharmacies and pharmacists that are a danger to the public safety and health?


Second Question of the Day, September 22, 2013 A Repeat Question--Why are More State Boards of Pharmacy Not Taking More Aggressive Action Against Compounding Pharmacies and Pharmacist Who Violate Their State Laws, Rules, and Regulations on Compounding?


Question of the Day September 22, 2013 How many women will stop taking compounded hormones after reading the eye-opening investigative report, "The Hormone Hoax Thousands Fall For" in the October 2013 More Magazine?


Tuesday, September 17, 2013

Make penalties matter Tuesday, September 17, 2013

read more at Boston Hearld

Women in Government Regional Conference in OKC on September 19-21, 2013, Includes Presentation on Potential dangers of Compounding Medications


9:30 am – 10:15 am  Potential Dangers of Compounding Medications
Facilitated By: Representative Laura Hall
  Vice Chair & Treasurer, Women In Government Board of Directors
  Alabama State Legislature
   Jennifer Gudeman, PharmD
   Ther-Rx
    Casey Younkin, MD
   Associate Professor, Division of General OB/GYN
SIU School of Medicine, Department of OB/GYN
This session will address the issues of contaminated compounded drugs in
need of enhanced FDA oversight.

complete agenda here 
    ____________________________________

Monday, September 16, 2013

IACP Summarizes the House Compounding Bill Draft, Released on Sept. 12, 2013


On September 12, 2013, Rep. Morgan Griffith of Virginia (R-VA), Diana DeGette (D-CO) and Gene Green (D-TX) released a bipartisan legislation, House Resolution 3089, the “Compounding Clarity Act of 2013.”

Over the past few months, the International Academy of Compounding Pharmacists (IACP) has worked closely with the House Energy & Commerce Committee on behalf of our membership in an effort to incorporate needed provisions that Senate S. 959 does not address.
IACP is continuing to review the Bill, and believes it offers a significant improvement over the Senate bill. We look forward to continued collaboration with Congress on this draft. There are some issues that will need to be resolved, including those that pertain to federal vs. state authority, and we are eager to begin that process.  

continue reading here

Thursday, September 12, 2013

URGENT! FDA Enforcement Report--Recall from Wedgewood Pharmacy on Pentosan Polysulfate Sodium week of September 11, 2013


Enforcement Report - Week of September 11, 2013

     

    Product Detail

Product DescriptionPentosan Polysulfate Sodium (K9) 150 mg/ml aqueous solution for injection, for Veterinary Use only 10 mL Sterile amber vials Refrigerated Storage required. Item Code PENTOS-INJ007VC This preparation is dispensed with a prescription label, so each vial would be individually labeled with specific information containing not only the drug name, strength, etc. but also the patient name, prescriber name, and directions for use.
Recall NumberV-312-2013
ClassificationClass II
Code InfoLot number 20130618@409, Beyond Use Date 12/15/2013
Product Distributed Qty34 units
Reason For RecallRoutine endotoxin testing of this batch indicated that the finished injection solution contained a concentration of endotoxins exceeding established endotoxin concentration limits. A second sample tested from this same lot confirmed the higher than expected endotoxin concentration.

Event Detail

Event Id66042
Product TypeVeterinary
StatusOngoing
Recalling FirmWedgewood Village Pharmacy, Inc.
CitySwedesboro
StateNJ
CountryUS
Voluntary / MandatedVoluntary: Firm Initiated
Recall Initiation Date2013-06-28
Initial Firm Notification of Consignee or PublicTelephone
Distribution PatternNationwide